Template:Hormone levels with estradiol and estradiol esters by intramuscular injection
Appearance
(Redirected from Template:Hormone levels with estradiol esters by intramuscular injection)
-
Tritiated estradiol radioactivity in blood with a single intramuscular injection of 1.5 to 2.8 μg tritiated estradiol in aqueous solution in four women.[1] Peak blood radioactivity occurred within 15 minutes in three of the women and in the remaining woman after 2 hours.[1] Source: Davis et al. (1963).[1]
-
Estradiol levels after a single intramuscular injection of 5 mg estradiol benzoate, 5 mg estradiol valerate, or 5 mg estradiol cypionate in oil solution in women.[3] Source: Oriowo et al. (1980).[3]
-
Simplified curves of estradiol levels after intramuscular injection of different 5 mg estradiol benzoate, 5 mg estradiol valerate, 5 mg estradiol cypionate, or 10 mg estradiol enanthate in oil solution in women.[4] Source: Garza-Flores (1994).[4]
-
Vaginal cornification with a single intramuscular injection of 5 mg estradiol benzoate, 5 mg estradiol dipropionate, or 5 to 25 mg estradiol cypionate in oil solution in women.[5] Source: Schwartz & Soule (1955).[5]
-
Estradiol levels after a short intravenous infusion of 20 mg estradiol in aqueous solution or an intramuscular injection of an equimolar dose of estradiol benzoate, estradiol valerate, or estradiol undecylate in oil solution in women.[6][7] Sources: Geppert (1975) and Leyendecker et al. (1975).[6][7]
-
Estradiol levels after a single intramuscular injection of 10 mg estradiol valerate or 100 mg estradiol undecylate in oil solution.[8] Source: Vermeulen (1975).[8]
-
Estradiol and testosterone levels after a single intramuscular injection of 320 mg polyestradiol phosphate in aqueous solution in men with prostate cancer.[9] Source: Stege et al. (1996).[9]
-
Estradiol levels after the fourth dose during continuous therapy with estradiol and progesterone microspheres in aqueous suspension by intramuscular injection once per month in menopausal women.[10][11] Source: Espino y Sosa et al. (2019).[10]
Template documentation
See also
References
- ^ a b c Davis ME, Wiener M, Jacobson HI, Jensen EV (December 1963). "Estradiol metabolism in pregnant and nonpregnant women". Am. J. Obstet. Gynecol. 87 (8): 979–90. doi:10.1016/0002-9378(63)90091-7. PMID 14089314.
- ^ a b c Jones TM, Fang VS, Landau RL, Rosenfield R (December 1978). "Direct inhibition of Leydig cell function by estradiol". J. Clin. Endocrinol. Metab. 47 (6): 1368–73. doi:10.1210/jcem-47-6-1368. PMID 122429.
- ^ a b Oriowo MA, Landgren BM, Stenström B, Diczfalusy E (April 1980). "A comparison of the pharmacokinetic properties of three estradiol esters". Contraception. 21 (4): 415–24. doi:10.1016/S0010-7824(80)80018-7. PMID 7389356.
- ^ a b Garza-Flores J (April 1994). "Pharmacokinetics of once-a-month injectable contraceptives". Contraception. 49 (4): 347–59. doi:10.1016/0010-7824(94)90032-9. PMID 8013219.
- ^ a b Schwartz MM, Soule SD (July 1955). "Estradiol 17-beta-cyclopentylpropionate, a longacting estrogen". Am. J. Obstet. Gynecol. 70 (1): 44–50. doi:10.1016/0002-9378(55)90286-6. PMID 14388061.
- ^ a b Gerhard Geppert (1975). Untersuchungen zur Pharmakokinetik von Östradiol-17β, Östradiol-Benzoat, Östradiol-Valerianat und Östradiol-Undezylat bei der Frau: der Verlauf der Konzentrationen von Östradiol-17β, Östron, LH und FSH im Serum [Studies on the pharmacokinetics of estradiol-17β, estradiol benzoate, estradiol valerate, and estradiol undecylate in women: the progression of serum estradiol-17β, estrone, LH, and FSH concentrations]. pp. 1–34. OCLC 632312599.
- ^ a b Leyendecker G, Geppert G, Nocke W, Ufer J (May 1975). "Untersuchungen zur Pharmakokinetik von Östradiol-17β, Östradiol-benzoat, Östradiol-Valerianat un Östradiol-Undezylat bei der Frau: Der Verlauf der Konzentration von Östradiol-17β, Östron, LH und FSH im Serum" [Estradiol 17β, estrone, LH and FSH in serum after administration of estradiol 17β, estradiol benzoate, estradiol valeriate and estradiol undecylate in the female]. Geburtshilfe Frauenheilkd (in German). 35 (5): 370–374. ISSN 0016-5751. PMID 1150068.
- ^ a b Vermeulen A (1975). "Longacting steroid preparations". Acta Clin Belg. 30 (1): 48–55. doi:10.1080/17843286.1975.11716973. PMID 1231448.
- ^ a b Stege R, Gunnarsson PO, Johansson CJ, Olsson P, Pousette A, Carlström K (May 1996). "Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin) in prostatic cancer patients". Prostate. 28 (5): 307–10. doi:10.1002/(SICI)1097-0045(199605)28:5<307::AID-PROS6>3.0.CO;2-8. PMID 8610057. S2CID 33548251.
- ^ a b Espino y Sosa, Salvador; Cortés Fuentes, Myriam; Alejandro Gómez Rico, Jacobo; Cortés Bonilla, Manuel (2019). "Non-polymeric Microspheres for the Therapeutic Use of Estrogens: An Innovative Technology". In Khan, Wahid Ali (ed.). Estrogen. ISBN 978-1-83880-867-9.
- ^ "Juvenum E (estradiol) – Medicamentos PLM". Medicamentos PLM. Archived from the original on 18 September 2018. Retrieved 17 September 2018.